WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

CONGENITAL DYSERYTHROPOIETIC ANEMIA (TYPE 2) – CASE REPORT OF A RARE HEMATOLOGICAL DISORDER

Dr. Sunderesh Kamal Chander U., Dr. Neelayadakshi B.*, Dr. Niveditha E. N., Dr. Evelyn Elizabeth Ebenezer and Dr. Muthuvel E.

Abstract

Congenital dyserythropoietic anemia (CDA) comprise a heterogeneous group of rare inhereditary disorders characterized by ineffective erythropoiesis and distinct morphologic abnormalities of the erythroblasts in the bone marrow. Three types of CDA are known: types 1, 2 and 3. The genes responsible for types 1 and 2 have recently been identified as CDAN1 and SEC3B. The wide variety of phenotypes observed in these patients makes the diagnosis difficult; identification of the genetic variants is crucial in differential diagnosis and clinical management. We reported a 19 year old male visited medicine department with complaints of easy fatiguability and joint pain involving bilateral knee. On systemic examination hepatosplenomegaly was present. On hematological examination show a classical bone-marrow picture with binucleated erythroblasts and Ham’s test was positive. Hence we diagnosed it as a case of Congenital Dyserythropoietic anemia - type II.

Keywords: Congenital Dyserythropoietic anemia, peripheral blood smear, bone marrow aspiration, binucleated erythroblasts and Ham’s test.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More